Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Salcedo M et al. | The marine sphingolipid-derived compound ES 285 triggers an atypical cell death pathway. | 2007 | Apoptosis | pmid:17191124 |
Sánchez AM et al. | Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation. | 2008 | Eur. J. Pharmacol. | pmid:18343365 |
Pruett ST et al. | Biodiversity of sphingoid bases ("sphingosines") and related amino alcohols. | 2008 | J. Lipid Res. | pmid:18499644 |
Baird RD et al. | Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. | 2009 | Mol. Cancer Ther. | pmid:19509256 |
Bertea M et al. | Deoxysphingoid bases as plasma markers in diabetes mellitus. | 2010 | Lipids Health Dis | pmid:20712864 |
Garofalo K et al. | Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. | 2011 | J. Clin. Invest. | pmid:22045570 |
Scherer SS | The debut of a rational treatment for an inherited neuropathy? | 2011 | J. Clin. Invest. | pmid:22045569 |
Rotthier A et al. | Characterization of two mutations in the SPTLC1 subunit of serine palmitoyltransferase associated with hereditary sensory and autonomic neuropathy type I. | 2011 | Hum. Mutat. | pmid:21618344 |
Merrill AH | Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. | 2011 | Chem. Rev. | pmid:21942574 |
Schöffski P et al. | Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies. | 2011 | Cancer Chemother. Pharmacol. | pmid:21465314 |